French pharmaceutical company Sanofi is in talks with Swiss drugmaker Actelion, but a deal is not imminent, sources confirmed to CNBC on Wednesday.
U.S. shares of Actelion and Sanofi were down 9 percent and 2.5 percent, respectively, on Wednesday.
It’s unclear what price Sanofi might pay or what structure is envisioned, but the deal could value Actelion as much as $30 billion, according to The Wall Street Journal, which first reported on the talks and cited people familiar with the matter.
On Tuesday, Johnson & Johnson ended its discussions with Actelion regarding a possible transaction. Actelion told J&J it was confident it could attract a higher offer than the 250 Swiss francs per share the U.S. company had offered, Reuters reported.
In August, Sanofi, eager for deals to broaden its drug lineup, was trumped by Pfizer’s $14 billion bid for U.S. cancer drug company Medivation.
Source: CNBC
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.
